Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 3,000 Shares of Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $4.01, for a total transaction of $12,030.00. Following the transaction, the director now directly owns 141,950 shares of the company’s stock, valued at $569,219.50. This represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Monday, October 28th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $3.72, for a total value of $11,160.00.

MaxCyte Price Performance

MaxCyte stock opened at $4.11 on Tuesday. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.55. The stock’s 50 day moving average price is $3.77 and its 200 day moving average price is $4.02. The company has a market cap of $434.39 million, a PE ratio of -12.09 and a beta of 1.37.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter last year, the firm posted ($0.11) EPS. On average, equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

A number of institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of MaxCyte by 24.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company’s stock worth $1,659,000 after purchasing an additional 83,025 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after buying an additional 5,927 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of MaxCyte by 15.3% in the second quarter. Rhumbline Advisers now owns 157,616 shares of the company’s stock worth $618,000 after acquiring an additional 20,864 shares during the last quarter. American Century Companies Inc. lifted its position in shares of MaxCyte by 10.7% in the second quarter. American Century Companies Inc. now owns 144,110 shares of the company’s stock valued at $565,000 after acquiring an additional 13,904 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of MaxCyte by 13.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock valued at $3,961,000 after acquiring an additional 121,090 shares during the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.